




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : KUTRYK et al.
 Serial No. : 09/808,867
 Filed : 15 March 2001
 Publication No. : US 2002/0049495 A1
 For : MEDICAL DEVICE WITH COATING THAT
 PROMOTES ENDOTHELIAL CELL
 ADHERENCE
 Examiner : Urmi Chattopadhyay
 Group Art Unit : 3738

| | |
|---|--|
| CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8 I hereby certify that this paper is being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. | |
| <u>John M. Genova</u> Attorney Name | <u>32,224</u> PTO Reg. No. |
|  Signature | <u>November 3, 2005</u> Date of Signature |

Mail Stop RCE
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

**DECLARATION OF MICHAEL JOHN BRADLEY KUTRYK
 UNDER 37 C.F.R. § 1.132**

Sirs:

1. I, Michael John Bradley Kutryk, a citizen of Canada, residing at 106 Millwood Road, Toronto, Canada M4S 1J7, Canada declare as follows:
2. I am employed as a physician and professor specializing in interventional cardiology at St. Michael's Hospital, a teaching affiliate of the University of Toronto Medical School, Toronto, Canada.
3. I have my own research laboratory at St. Michael's Hospital and have numerous publications in the field of cardiovascular research. My curriculum vitae is attached (Exhibit 1).

4. I am also a co-inventor of the invention disclosed by and claimed in the referenced application. As such, I am familiar with the state of the art at the time the invention was made and have direct knowledge of the referenced application and its prosecution history.
5. I understand that the Examiner has issued a final Office Action in the referenced application and has rejected the pending claims as obvious over the publication to Dekker A., et al., *Thrombosis and Haemostasis*, "Improved Adhesion and Proliferation of Human Endothelial Cells on Polyethylene Precoated with Monoclonal Antibodies Directed Against Cell Membrane Antigens and Extracellular Matrix Proteins", F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 66(6): 715-724 (1991) ("Dekker") in combination with US 5,310,669 to Richmond et al. ("Richmond") and, in some instances, with yet another reference.
6. For the reasons set forth herein, I respectfully yet strongly disagree with the Examiner. At the time the claimed invention was made, a person of ordinary skill in the art would not have been motivated to combine Dekker and Richmond with a reasonable expectation of successfully arriving at the claimed invention.
7. Dekker tried to solve a problem using *ex vivo* "seeded vascular grafts," which is not the subject matter of the claimed invention. Richmond discloses fullerene-coated surfaces such as those of Petri dishes, for use, for example, in culturing homogeneous cell populations *in vitro*. However, there is no suggestion in Richmond to coat a medical device for implantation which is designed to capture progenitor and endothelial cells *in vivo* to form functional endothelium *in situ*.
8. Even the Examiner has acknowledged that the respective disclosures of Dekker and Richmond are limited to *in vitro* studies under static conditions. However, at page 12 of the final Office Action, the Examiner states that combination of prior art, including Dekker and Richmond, would produce a structure that "allows for *in vivo* attachment of cells".
9. At the time the claimed invention was made, a person of ordinary skill in the art would have reasonably expected that shear forces, i.e., *in vivo* under conditions of flow, would quickly wash off any surface-adsorbed antibodies as disclosed by Dekker and Richmond. Therefore, contrary to the Examiner's position, *in vivo* capture of circulating endothelial cells and proliferation of captured cells to bring about an inhibition of restenosis would not and could not have reasonably been expected in view of the prior art. Therefore, it is my opinion that a person of ordinary skill in the art would not have been motivated to combine Dekker and Richmond with a reasonable expectation of successfully producing the claimed medical device for implantation into a patient, wherein the medical device has a coating comprising a matrix layer and antibodies with specificity to bind cell surface antigens of endothelial cells, or progenitors thereof, *in vivo*.

10. Our experiments have surprisingly shown that a single type of antibody which binds a specific cell membrane antigen can be utilized to capture cells *in vitro* or *in vivo*, and support proliferation of the immobilized cells. This is evident by *in vitro* and *in vivo* experiments that my laboratory have performed with different substrates of materials, typically used in medical devices, which were tested using antibodies and matrices of the claimed invention on the following configurations: (a) uncoated material substrates of medical devices; (b) material substrates of medical devices coated with a matrix; and (c) medical devices coated with a matrix and antibody.
11. It took Applicants numerous attempts, and entailed many hours of difficult experimentation, to identify the types of biocompatible matrices as well as the types of antibodies suitable for coating medical devices to promote reendothelialization of an implant at the site of injury and thus prevent restenosis. As stated in the specification, thickening of the blood vessels wall occurs after implantation of a stent due to smooth muscle cell proliferation (See e.g., page 11, lines 7-15).
12. Unexpectedly, our experiments have shown that the claimed medical devices inhibit restenosis. For example, experiments were conducted in which coated and uncoated stents were implanted into the coronary arteries in the hearts of male Yorkshire swine. The implants were left in the swine for a period of 28 days, at which time the arterial segments containing the implants were removed and processed for studies. Histological photomicrographs of cross-sections through coronary arteries of explants from these studies are shown in Figures 1A-1F (attached as Exhibit 2). Figures 1A, 1B and 1C are low magnification showing the circumference of the arteries, whereas Figures 1D, 1E and 1F, respectively, are a higher magnification from experiments of stents (medical devices):

| STENT SURFACE CONFIGURATIONS | CROSS-SECTION THROUGH CORONARY ARTERIES OF EXPLANTS | |
|--|---|----|
| no coating (bare 316L stainless steel stent) | 1A | 1D |
| a 316L stainless steel stent coated with a synthetic matrix of the invention, in this case a (carboxymethyl dextran ("Dextran") matrix | 1B | 1E |
| a 316L stainless steel stent coated with a Dextran matrix and anti-CD34 antibody | 1C | 1F |

As can be seen from the photomicrographs (Exhibit 2), the stents coated with Dextran and anti-CD34 antibody (Figures 1C and 1F) shows a remarkably thinner blood vessel wall and a larger luminal diameter than the uncoated or Dextran-coated devices (Figures 1A, 1B, 1D and 1E). Attached as Exhibits 3 and 4 are representative scanning electron micrographs of struts from stent explants which had been coated with Dextran, or coated with Dextran and anti-CD34 antibody prior to implantation into a swine artery. As can be seen in the micrographs taken at 1 hour after implantation (Exhibit 3), the Dextran/antibody-coated stent was rapidly covered with progenitor endothelial cells when compared to the stent coated with Dextran alone, and by 48 hours (Exhibit 4), it shows a confluent layer of endothelium when compared to Dextran alone.

13. Similarly, we performed *in vitro* experiments using stainless steel discs coated with a fullerene matrix with or without a layer of anti-CD34 antibodies attached to the fullerene matrix. Progenitor cells isolated from blood donated by healthy human volunteers were isolated with anti-CD34 antibody attached to magnetic beads from the samples, and incubated with the fullerene-coated and fullerene-plus-antibody-coated samples for 7 days. The samples were fixed in 2% paraformaldehyde, washed and stained with a nuclear stain, Propidium iodide, and counter-stained with anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2, specific to endothelial cells) secondary antibody conjugated with fluorescein isothiocyanate (FITC) and visualized under a confocal microscope. Photomicrographs of each sample were taken. Figures 2A-2D (Exhibit 5) provide representative data from the experiments. As shown in Figures 2A and 2B, the fullerene-coated stainless steel discs did not show progenitor cell attachment to the discs, as no significant VEGFR-2/FITC fluorescence was present on this disc. However, the fullerene-antibody-coated disc in Figures 2C and 2D show numerous adherent cells on the disc as demonstrated by the fluorescence emanating from the cells' surfaces.
14. Moreover, we conducted similar studies using expanded polytetrafluoroethylene (ePTFE) as a substrate coated with biocompatible matrices, including Dextran and gelatin with or without anti-CD34 antibodies. The graft models were incubated with human progenitor cells in an *in vitro* environment and samples were taken at various times post-incubation. Exhibit 6 is a graph showing the number of cells that adhered to the surface of the graft model at the various times. The graph shows that the number of cells attached to the surface of the samples was significantly greater for those samples coated with a matrix and the antibody. Exhibit 7 shows a bar graph of the results in which it is evident that the claimed medical device coated, with a layer of matrix and an anti-CD34 antibody, shows a 5-fold increase in the amount of cells attached on the surface as compared to bare ePTFE.
15. With specific regard to Dekker, a polyethylene substrate is coated with two different types of adsorbed antibodies (Fab fragment), i.e., one antibody against an endothelial cell surface antigen and a second antibody directed against

- extracellular matrix protein. Dekker reports that cell proliferation was completely absent and even detachment of the endothelial cells occurs on the polyethylene substrate coated with adsorbed antibodies. Dekker further reports that two types of antibodies are required to obtain endothelial cell proliferation *in vitro* (see page 722; column 1, lines 52-56; column 2, last paragraph; Figs. 5 and 6). Contrary to Dekker, our data show that a single type of antibody which binds a specific cell membrane antigen can be utilized to capture cells *in vitro or in vivo*, and support proliferation of the immobilized cells in both instances. This is evident by *in vitro* and *in vivo* experiments. Additionally, Dekker concluded that the use of whole antibody would not be feasible, since the “[p]latelet activation by adsorbed intact antibody is probably mediated by the Fc parts of the IgG molecules.” This is contrary to our findings, as all of the *in vivo* experiments presented herewith were performed using intact antibodies on the coating. As such Dekker can be said to teach away from the claimed invention.
16. With specific regard to Richmond, the disclosure is limited to cell culture substrates for *in vitro* biological applications, e.g., growing cells in Petri dishes. Richmond is silent with respect to any actual medical application, and there is nothing in Richmond to suggest that cells growing on the static culture substrates disclosed by Richmond could withstand shear forces *in vivo* under conditions of flow. Therefore, a person of ordinary skill in the art would reasonably expect that any surface-adsorbed antibodies disclosed by Richmond would be quickly washed off by such *in vivo* shear forces. Accordingly, at the time the claimed invention was made, Richmond did not and could not offer a reasonable expectation of successfully using a fullerene-coated substrate to promote the attachment of endothelial cells *in vivo* in the first place, which attachment would result in proliferation of the cells, and formation of functional endothelium *in vivo*.
 17. Furthermore, Richmond does not disclose a fullerene matrix with specific antibodies attached thereto for binding endothelial cells. Our own studies presented above under paragraphs 12-14, particularly those in paragraph 13, show that medical devices having different synthetic or naturally occurring matrices in the coating, for example, Dextran, fullerene and gelatin, in combination with the antibody of the claimed invention resulted in specific binding to an endothelial cell surface antigen, proliferation of the bound cells and inhibition of restenosis. These results were unexpected and not predictable from Richmond, whether taken alone or in combination with Dekker.
 18. Finally, our data described in paragraph 13 above show that a single antibody specific to an endothelial cell surface antigen in combination with a fullerene matrix in the coating of the medical device promotes increased binding and proliferation of endothelial cells, and is contrary to the data in Dekker et al. and Richmond et al. which, respectively, assert that two antibody types are needed for *in vitro* cell growth (Dekker at Abstract) and that growth factors are required in the incubation medium to promote *in vitro* cell growth (Richmond et al. col. 3 lines 48-64).

19. In my experience, it is not possible to predict with reasonable certainty the properties that a medical device will exhibit *in vivo* when compared to *in vitro* since the conditions vary tremendously. The fact that the present coating on the medical device yielded the reported results was unexpected and could not have been reasonably predicted.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements, and the like, so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of any patent issued thereon.

Signed in full: _____

Michael John Bradley Kutryk

Dated: _____

Oct 17-05.



CURRICULUM VITAE

Michael John Bradley Kutryk
106 Millwood Road
Toronto, Ontario
M4S 1J7

Current Appointment: Assistant Professor
Clinician Scientist
St. Michael's Hospital
30 Bond Street
Toronto, Ontario
Canada, M5B 1W8
Tel: 416 864 5174

A. EDUCATION

- | | |
|-----------|--|
| 1995-1999 | Interventional Cardiology Fellow – Post-Doctoral Fellow Clinician/Scientist of the Medical Research Council of Canada University Hospital Rotterdam – Dijkzigt Erasmus University Rotterdam, The Netherlands |
| 1995 | Subspecialty Training in Cardiology Royal Victoria Hospital, McGill University Montreal, Canada |
| 1994 | Speciality Certification in Internal Medicine Royal Victoria Hospital, McGill University Montreal, Canada |
| 1991 | Ph.D. (Cardiovascular Physiology) University of Manitoba Winnipeg, Canada |
| 1990 | M.D. University of Manitoba Winnipeg, Canada |
| 1984 | Masters of Science (Cardiovascular Physiology) University of Manitoba Winnipeg, Canada |

1981 Bachelor of Science (Joint Chemistry and Microbiology)
First Class Honors
University of Manitoba
Winnipeg, Canada

B. AWARDS AND SCHOLARSHIPS

2004 Young Investigator Award - 2004
Canadian Cardiovascular Society
Ottawa, Canada

1995-1999 Medical Research Council of Canada Clinician-Scientist Award
University Hospital Rotterdam – Dijkzigt
Erasmus University
Rotterdam, The Netherlands

1995 Paul P. David de Merck Frosst
Bourse de Perfectionnement
Association des Cardiologues du Quebec
Montreal, Canada

1995 Dr. Benjamin Levitan Award
Royal Victoria Hospital
Montreal, Canada

1991 E.L. Drewry Memorial Award for Research Excellence
University of Manitoba
Winnipeg, Canada

1991 St. Boniface Hospital Research Foundation Inc.
Award for Research Excellence in Cardiovascular Biology
Winnipeg, Canada

1988 Excellence in Research Award
University of Manitoba Faculty of Medicine
Student Research Awards Day Poster Competition
Winnipeg, Canada

1987-90 Canadian Heart Foundation Medical Scientist Scholarship
Winnipeg, Canada

| | |
|---------|--|
| 1985-86 | Canadian Heart Foundation Studentship Winnipeg, Canada |
| 1984-85 | Manitoba Health Research Council Studentship Winnipeg, Canada |
| 1982-84 | Canadian Heart Foundation Studentship Winnipeg, Canada |
| 1980 | Proctor and Gamble Award University of Manitoba Winnipeg, Canada |
| 1980-81 | Joseph Hogg Scholarship in Chemistry University of Manitoba Winnipeg, Canada |

C. RESEARCH GRANTS

| | |
|--------------|--|
| 2003-present | Heart and Stroke Foundation of Ontario Research Operating Grant Toronto, Ontario |
|--------------|--|

D. RESIDENCIES, FELLOWSHIPS

| | |
|-----------|---|
| 1990-1993 | Resident, Internal Medicine Royal Victoria Hospital Montreal, Canada |
| 1993-1994 | Resident, Cardiology Royal Victoria Hospital Montreal, Canada |
| 1994-1995 | Chief Resident, Cardiology Royal Victoria Hospital Montreal, Canada |
| 1995-1999 | Interventional Cardiology Fellow Post-Doctoral Fellow Molecular Biology University Hospital Rotterdam -Dijkzigt Erasmus University Rotterdam, The Netherlands |

1999-2000 Research Fellow, Cardiology
 St. Michael's Hospital
 Toronto, Canada

2000-2001 Cardiology Resident
 University Health Network
 Toronto, Canada

E. TEACHING APPOINTMENTS

1983-1986 Lecturer; Cardiovascular Physiology
 School of Medical Rehabilitation
 University of Manitoba
 Winnipeg, Canada

F. PROFESSIONAL AFFILIATIONS

Fellow of the Royal College of Physicians of Canada

International Society for Heart Research; Member

Associate Scientist, R. Samuel McLaughlin Centre for Molecular Medicine

G. EDITORIAL BOARDS

1. Cardiovascular Radiation Medicine, Elsevier Science Inc. New York, NY.

H. PUBLICATIONS

Full Length Papers:

1. Jamieson JC, Kutryk MJB. Studies on the effect of phenylbutazone and salicylate on the rates of synthesis of albumin and acute-phase α_1 -acid glycoprotein by rat liver slices. Biochem Med 1981;23:292-301.
2. Jamieson JC, Kutryk MJB, Woloski BM, Kaplan HA. Studies on the effect of indomethacin and sulfinpyrazone on the rates of synthesis of albumin and acute phase α_1 -acid glycoprotein by rat liver slices. Biochem Med 1982;28:176-187.

3. Pierce GN, Kutryk MJB, Dhalla NS. Alterations in calcium binding and composition of the cardiac sarcolemmal membrane in chronic diabetes. *Proc Natl Acad Sci U.S.A.* 1983;80:5412-5416.
4. Pierce GN, Kutryk MJB, Dhalla KS, Beamish RE, Dhalla NS. Biochemical alterations in the heart after exhaustive swimming in rats. *J Appl Physio* 1984;57:326-331.
5. Tuana BS, Kutryk MJB, Elimban V, Wikman-Coffelt J, Dhalla NS. Influence of myosin antiserum on heart sarcolemmal Ca^{2+} or Mg^{2+} ATPase activity. *Res Commun Chem Path Pharm* 1984;45:297-300.
6. Roman S, Kutryk MJB, Beamish RE, Dhalla NS. Lysosomal changes during the development of catecholamine induced cardiomyopathy. In *Pathogenesis of Stress Induced Heart Disease*, ed. by RE Beamish, V Panagia, NS Dhalla, and Martinus Nijhoff. Boston 1984;270-280.
7. Singal PK, Segstro R, Singh RP, Kutryk MJB. Changes in lysosomal morphology and enzyme activities during the development of adriamycin induced cardiomyopathy. *Can J Cardiol* 1985;1:139-147.
8. Kutryk MJB, Dhalla NS. Alterations in cardiac lysosomal hydrolases following induction of the calcium paradox. *Can J Physio Pharmacol* 1987;65:2175-2181.
9. Kutryk MJB, Pierce GN, Dhalla NS. Alterations in heart and serum lysosomal activities in streptozotocin-induced diabetes. *Basic Res Cardiol* 1987;82:271-278.
10. Kutryk MJB, Pierce GN. Stimulation of sodium-calcium exchange by cholesterol incorporation into isolated cardiac sarcolemmal vesicles. *J Biol Chem* 1988;263:13167-13172.
11. Pierce GN, Langer GA, Wright GB, Kutryk MJB. Calcium is rapidly exchangeable in cultured vascular smooth muscle cells from rabbit aorta. *J Mol Cell Cardiol* 1989;21:889-899.
12. Pierce GN, Afzal N, Kroeger EA, Lockwood MK, Kutryk MJB, Eckhert CD, Dhalla NS. Cataract formation is prevented by administration of verapamil to diabetic rats. *Endocrinology* 1989;125:730-735.
13. Meng H, Kutryk MJB, Pierce GN. Effect of platelet-activating factor (PAF) on sodium-calcium exchange in cardiac sarcolemmal vesicles. *Mol Cell Biochem* 1990;92:45-51.

14. Kutryk MJB, Maddaford TG, Ramjiawan B, Pierce GN. Oxidation of membrane cholesterol alters active and passive transsarcolemmal calcium movement. *Circ Res* 1991;68:18-26.
15. Liu K, Maddaford TG, Ramjiawan B, Kutryk MJB, Pierce GN. Effects of cholesterol oxidase on cultured vascular smooth muscle cells. *Mol Cell Biochem* 1991;108:39-48.
16. Liu K, Ramjiawan B, Kutryk MJB, Pierce GN. Effects of oxidative modification of cholesterol in isolated low density lipoproteins on cultured smooth muscle cells. *Mol Cell Biochem* 1991;108:49-56.
17. Kutryk MJB, Pierce GN. Effects of low-density lipoprotein on calcium ion movements in cultured vascular smooth muscle cells. *Coronary Artery Disease* 1991;2:1093-1101.
18. Herrman JPR, Suryapranata H, den Heijer P, Gabriël L, Kutryk MJB, Serruys PW. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study. *J Thromb Thrombolysis* 1996;3:367-375.
19. von Birgelen C, Kutryk MJB, Gil R, Ozaki Y, Di Mario C, de Feyter PJ, Serruys PW. Quantification of the minimal luminal cross-sectional area after coronary stenting by two- and three-dimensional intravascular ultrasound versus edge detection and videodensitometry. *Am J Cardiol* 1996;78:520-525.
20. Kutryk MJB, Serruys PW. Antisense oligonucleotide therapy for the prevention of stent restenosis. The ITALICS trial. *Thoraxcenter J* 1996;8:46-48.
21. Kutryk MJB, Fitchett D. Hills sign in aortic regurgitation: Enhanced pressure wave transmission or artefact? *Can J Cardiol* 1997;13:237-240.
22. Camenzind E, Bakker WH, Ambroos R, van Geijlswijk IM, Boersma E, Kutryk MJB, Krenning EP, Roelandt JRTC, Serruys PW. Site-specific intracoronary heparin delivery in man after balloon angioplasty: A radioisotopic assessment of regional pharmacokinetics. *Circulation* 1997;96:154-165.
23. von Birgelen C, Kutryk MJB, Serruys PW. Three-dimensional intravascular ultrasound analysis of coronary stent deployment and in-stent neointimal volume: Current clinical practice and the concepts of TRAPIST, ERASER, and ITALICS. *J Invasiv Cardiol* 1998;10:17-26.
24. Deshpande NV, Sabaté M, Ligthart JMR, Kutryk MJB, Serruys PW. Stent implantation through a self-expanding stent - a case report. *Inter J Cardiovasc Intervent* 1998;1:45-48.

25. Mallus MT, Kutryk MJ, Prati F, von Birgelen C, de Feyter PJ, Roelandt JR, Serruys PW. Extent and distribution of atherosclerotic plaque in relation to major coronary side-branches: an intravascular ultrasound study in vivo. *Giornale Italiano de Cardiologia* 1998;28:961-969.
26. Kutryk MJB, Wardeh AJ, Knook AHM, Foley DP, van der Giessen WJ, Hamburger JN, van den Brand M, de Feyter PJ, Becker GJ, Serruys PW. First clinical experience with the R stent: a new highly flexible stainless steel tube intracoronary stent. *Inter J Cardiovasc Intervent* 1998;2:141-152.
27. Bruining N, Sabate M, de Feyter PJ, Kay IP, Ligthart J, Disco C, Kutryk MJ, Roelandt JR, Serruys PW. Quantitative measurements of in-stent restenosis: A comparison between quantitative coronary ultrasound and quantitative coronary angiography. *Catheter Cardiovasc Interv* 1999;48:133-142.
28. Carlier SG, van der Giessen WJ, Foley DP, Kutryk MJ, Rensing BJ, Carleton ML, Serruys PW. Stenting with a true bifurcated stent: acute and mid-term follow-up results. *Catheter Cardiovasc Interv* 1999;47:361-396.
29. Van Langenhove G, Vermeersch P, Serrano P, Kutryk MJ, Stockman D, Convens C, Van den Branden F, Vanagt E, Albertal M, Van den Heuvel P. Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up. *Can J Cardiol* 2000;16:473-480.
30. Kuliszewski MA, Kutryk MJB, Sandhu R, Fitchett D, Stewart DJ. DNA integrity and transgene expression after passage through the NOGA needle catheter used for therapeutic myocardial angiogenesis. *J Cardiovasc Intervent* 2000;3:167-172.
31. de Crom R, Wulf P, van Nimwegen H, Kutryk MJB, Visser P, van der Kamp A, Hamming J. Irradiated versus nonirradiated endothelial cells: effect on proliferation of vascular smooth muscle cells. *J Vasc Interv Radiol* 2001;12:855-861.
32. Foley DP, Kererakes D, te Riele JA, Nishimura N, Veldhof S, Fink S, Yeung A, van Hoogenhuyze D, Lansky AM, van Es GA, Kutryk MJ, Serruys PW. Acute and 6-month clinical and angiographic outcome after implantation of the ACS Duet stent for single-vessel coronary artery disease: Final results of the European and U.S. ACS Multi-link Duet Registry. *Catheter Cardiovasc Interv* 2001;54:25-33.

33. Kutryk MJB, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, de Feyter PJ, Bruining N, Sabate M, Serruys PW. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis. Results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. *J Am Coll Cardiol* 2002;39:281-287.
34. Strauss B, Li C, Whittingham H, Tio F, Kutryk M, Janicki C, Sparkes J, Turnlund T, Sweet W. Late effects of low-energy gamma-emitting stents in a rabbit iliac artery model. *Int J Radiat Oncol Biol Phys*. 2002;54:551-561.
35. van Haperen R, de Waard M, van Deel E, Mees B, Kutryk M, van Aken T, Hamming J, Grosveld F, Duncker DJ, de Crom R. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. *J Biol Chem*. 2002;277:48803-48807.
36. Kutryk MJB, Ramjiawan B. Plasma lipid and lipoprotein pattern in the Inuit of the Keewatin district of the Northwest Territories. *Mol Cell Biochem* 2003;246:121-127.
37. Verma S, Kuliszewski MA, Li SH, Szmítko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. *Circulation*. 2004;109:2058-2067.
38. Sandu R, Teichert-Kuliszewska K, Nag S, Proteau G, Robb MJ, Campbell IM, Kuliszewski MA, Kutryk MJB, Stewart DJ. Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat. *Cardiovasc Res*. 2004;64:115-24.
39. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, van der Giessen WJ, Regar E, de Feyter PJ, Davis HR, Rowland S, Kutryk MJ. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. *J Am Coll Cardiol*. 2005;45:1574-9.

Abstracts:

1. Helmann MA, Kaplan HA, Kutryk MJB, Jamieson JC. Effect of inflammation on rat serum sialyltransferase activity. *Proc Can Feb Biol Soc* 1981;24:309.
2. Pierce GN, Kutryk MJB, Dhalla NS. Calcium binding to sarcolemmal membranes isolated

from diabetic rat heart. *J Mol Cell Cardiol* 1982;14(I Suppl):56S.

3. Tuana BS, Kutryk MJB, Wikman-Coffelt J, Dhalla NS. Influence of myosin antibodies on serum sarcolemmal Ca^{2+} -dependent ATPase. *J Mol Cell Cardiol* 1982;14(I Suppl)65S.
4. Kutryk MJB, Pierce GN, Dhalla KS, Beamish RE, Dhalla NS. Subcellular Ca^{2+} transport in rat heart after exhaustive exercise. *Proc Can Fed Biol Soc* 1983;26:56.
5. Kutryk MJB, Dhalla NS. Alterations in lysosomal enzyme activities in rat heart during calcium paradox. *J Mol Cell Cardiol* 1983;15(I Suppl):390S.
6. Singal PK, Segstro RJ, Kutryk MJB, Singh R. Lysosomal hydrolases in adriamycin induced cardiomyopathy. *Fed Proc* 1984:43.
7. Kutryk MJB, Pierce GN. Stimulation of Na^{+} - Ca^{2+} exchange by cholesterol in isolated cardiac sarcolemmal vesicles. *J Mol Cell Cardiol* 1988;20(IV Suppl)40S.
8. Meng H, Kutryk MJB, Pierce GN. Stimulation of Na^{+} - Ca^{2+} exchange in cardiac sarcolemmal vesicles. *J Mol Cell Cardiol* 1989;21(II Suppl):113S.
9. Liu K, Ramjiawan B, Kutryk MJB, Pierce GN. Effects of cholesterol oxidase on cultured vascular smooth muscle cells. *J Mol Cell Cardiol* 1990;22(I Suppl):49S.
10. Liu K, Ramjiawan B, Kutryk MJB, Pierce GN. Effects of oxidatively modified lipoprotein (LDL) cholesterol on cultured smooth muscle cells. *J Mol Cell Cardiol* 1990;22(I Suppl):49S.
11. Kutryk MJB, Maddaford TG, Ramjiawan B, Pierce GN. Effect of cholesterol oxidation on cardiac sarcolemmal ion transport. *J Mol Cell Cardiol* 1990;22(I Suppl):19S.
12. Kutryk MJB. Effects of cholesterol and its oxidation products on Ca^{2+} transport in cardiac and vascular smooth muscle. *Physio Canada* 1991;22(3):128-129.
13. Kutryk MJB, Pierce GN. The effect of isolated lipoproteins on calcium movements in cultured smooth muscle cells from rabbit aorta. *J Mol Cell Cardiol* 1992;24(III Suppl):55S.
14. Nicosia A, von Birgelen C, de Feyter PJ, van der Giessen WJ, de Jaegere PT, Ligthart J, Kutryk M, de Vrey E, Roelandt JRTC, Serruys PW. On-line contour detection in electrocardiogram gated three-dimensional intracoronary ultrasound after coronary stenting. *Eur Heart J* 1996;17(Suppl):187.

15. Camenzind E, Bakker W, Reijs A, van Geijlswijk I, Boersma E, Kutryk M, Krenning E, Roelandt J, Serruys P. Evaluation of efficiency of local intra-coronary drug delivery following angioplasty in human: a radio-isotopic technique. *Eur Heart J* 1996;17(Suppl):370.
16. von Birgelen C, Kutryk MJB, Ozaki Y, Foley D, Mallus MT, Roelandt JRTC, de Feyter PJ, Serruys PW. Minimal lumen area measurement after stenting by two-dimensional and three-dimensional intracoronary ultrasound versus quantitative angiography. *Circulation* 1996;94(Suppl):I-200.
17. Kutryk MJB, de Groot MR, van den Brand M, Hamburger JN, van der Giessen WJ, Foley DP, de Feyter PJ, von Birgelen C, Camenzind E, Serruys PW. Feasibility of the local delivery of antisense oligonucleotide against *c-myc* for the prevention of in-stent restenosis: Acute results of the Thoraxcenter "ITALICS" trial. *Eur Heart J* 1997;18(Suppl):507.
18. Kutryk MJB, van Dortmont LMC, van Meegen JR, de Crom RPG, Wulf PS, Visser WJ, Hamming J, van der Giessen WJ, van der Kamp AWM. Endoluminal cell seeding with allogenic endothelial cells. *Endothelium* 1997;5:357.
19. de Crom RPG, Kutryk MJB, van Haperen R, van Nimwegen H, Hamming J, Grosveld FG, van der Kamp AWM. Genetic modification of endothelial cells for xenotransplantation: a novel approach to prevent restenosis. *Endothelium* 1997;5:357.
20. Kutryk MJB, de Crom RPG, van Dortmont LMC, Wulf PS, Visser P, Verdouw P, Hamming J, van der Kamp AWM, van der Giessen WJ. Endoluminal cell seeding of porcine arteries with allogenic endothelial cells. *J Mol Cell Cardiol* 1998;30(Suppl):A125.
21. Kutryk MJB, van Dortmont LMC, van Meegen JR, de Crom RPG, Wulf PS, Visser WJ, Serruys PW, Hamming J, van der Giessen WJ, van der Kamp AWM. Endoluminal cell seeding with allogenic endothelial cells. *Eur Heart J* 1998;19(Suppl):496.
22. Kutryk MJB, Serruys PW, Bruining N, Sabatè M, Ligthart J, van den Brand M, Hamburger JN, van der Giessen WJ, Foley DP, de Feyter PJ. Randomized trial of antisense oligonucleotide against *c-myc* for the prevention of restenosis after stenting: results of the Thoraxcenter "ITALICS" trial. *Eur Heart J* 1998;19(Suppl):569.
23. Serruys PW, Kutryk MJB, Bruining N, Sabatè M, Foley DP, van den Brand M, Hamburger JN, Van der Giessen WJ, Eijgelshoven MH, de Feyter PJ. Antisense oligonucleotide against *c-myc* administered with the Transport™ delivery catheter for the prevention of in-stent restenosis. Results of the randomized ITALICS trial. *Circulation* 1998;98(Suppl):I-363.

24. Bruining N, Sabate M, Desphande N, Disco C, Kutryk MJB, Eijgelshoven M, Roelandt JRTC, Ligthart JMR, de Feyter PJ. Quantitative measurements of coronary arteries and stents: comparison between ECG-gated intracoronary ultrasound and quantitative coronary angiography. *Circulation* 1998;98(Suppl):I-230.
25. Sandhu R, Teichert-Kuliszewska K, Kuliszewski MA, Campbell AIM, Kutryk MJB, Stewart DJ. Alterations in expression of the angiopoietins after myocardial infarction in the rat: evidence for an angiogenic role for angiopoietin-2. *Eur Heart J* 2000;21(Suppl):356.
26. Kutryk MJB, Kuliszewski MA, Fitchett D, Stewart DJ. In vivo and in vitro assessment of the integrity of DNA and cells after injection through the NOGA needle catheter. *Am J Cardiol* 2000;86(Suppl 8A):85i.
27. Kutryk MJB, Sweet WL, Turnlund T, Tio FO, Strauss BH. A new γ -emitting Pd-103 stent prevents coronary artery in-stent restenosis in a swine model. *Am J Cardiol* 2000;86(Suppl 8A):124i.
28. Strauss BH, Li C, Whittingham H, Kutryk MJB, Sweet WL, Turnlund T, Tio FO. Late effects of a new γ -emitting Pd-103 stent in a rabbit iliac artery model. *Am J Cardiol* 2000;86(Suppl 8A):125i.
29. Cheema A, Kutryk M, Chisolm R, Fitchett D, Stewart DJ. Assessment of left ventricular regional wall motion by three-dimensional electromechanical NOGA mapping: correlation with contrast left ventriculography. *Can J Cardiol* 2000;16(Suppl F):178F.
30. Zhao YD, Kutryk MJB, Robb M, Ng DS, Wu JS, Stewart DJ. Cell-based gene therapy using a novel angiogenic and vascular maturation factor, angiopoietin-1, improves survival in experimental pulmonary hypertension. *Can J Cardiol* 2000;16(Suppl F):155F.
31. Kuliszewski MA, Sandhu R, Kutryk MJB, Fitchett DH, Stewart DJ. Transgene expression following passage of plasmid DNA through the NOGA needle injection catheter: effect of injection pressure. *Can J Cardiol* 2000;16(Suppl F):156F.
32. Sandhu R, Kutryk MJB, Campbell AIM, Salasidis G, Leclerc Y, Geranmaygan A, Cheema A, Fitchett DH, Stewart DJ. The effects of angiogenic gene therapy on coronary collateral formation in a porcine model of chronic myocardial ischemia: a randomized, blinded, placebo-controlled study. *Can J Cardiol* 2000;16(Suppl F):181F.
33. Zhao YD, Campbell AIM, Robb M, Ng D, Stewart DJ, Kutryk M. Cell-based angiopoietin-1 gene transfer improves survival and pulmonary haemodynamics in

monocrotaline-induced pulmonary hypertension Eur Heart J 2001;22(Suppl S):624.

34. Sandhu R, Kutryk MJB, Teichert-Kuliszewska K, Kuliszewski MA, Campbell AIM, Stewart DJ. Reciprocal changes in the expression of the angiopoietins after myocardial infarction in the rat: evidence that angiopoietin-2 may play a role in angiogenesis. Can J Cardiol 2000;16(Suppl F):223F.
35. Kuliszewski MA, Kutryk MJB, Fitchett D, Stewart DJ. An in vivo and in vitro assessment of integrity of plasmid DNA and cells after passage through the NOGA needle catheter: A potential gene delivery system. J Am Coll Cardiol 2001;37(Suppl A):43A-44A.
36. Kassam S, Kutryk M, Campbell A, Camack N, Latter D, Errett L, Chisholm R, Fitchett D, Stewart DJ. Hybrid gene therapy in patients turned down for coronary bypass surgery: An option for no option patients? J Am Coll Cardiol 2001;37(Suppl A):72A-73A.
37. Strauss BH, Li C, Whittingham HA, Tio FO, Kutryk MJB, Sparkes JD, Turnlund T, Sweet WL. Late effects of low-energy gamma emitting stents in a rabbit iliac injury model. J Am Coll Cardiol 2001; 37(Suppl A):330A.
38. Kutryk MJB, Sandhu R, Teichert-Kuliszewska K, Kuliszewski MA, Nag S, Campbell AIM, Stewart DJ. Temporal and spatial localization of the angiopoietin-Tie-2 system after myocardial infarction in the rat: Evidence of a role for Ang-2 in angiogenesis. J Am Coll Cardiol 2001;37(Suppl A):367A.
39. Kutryk M, Sandhu R, Campbell A, Salasidis G, Leclerc Y, Cheema A, Fitchett D, Stewart D. Angiogenic gene therapy for the induction of coronary collateral formation in a porcine model of chronic myocardial ischemia: A randomized, blinded, placebo-controlled study. Molecular Therapy 2001;3:S312.
40. Camack N, Dunne R, Kassam S, Kutryk M, Campbell A, Latter D, Errett L, Chisholm R, Fitchett D, Freeman M, Stewart DJ. Hybrid gene therapy in patients turned down for coronary bypass surgery: An option for no option patients? Can J Cardiol 2001;17(Suppl C):207C.
41. Cheema A, Geramaygan A, Sandhu R, Kutryk M, Fitchett D, Stewart D. Electromechanical mapping in a porcine model of myocardial ischemia. Validation with blood flow, echocardiography and pathology. Can J Cardiol 2001;17(Suppl C):126C.
42. Kutryk MJB, Sandhu R, Salasidis G, Campbell AIM, Leclerc Y, Cheema A, Koletar M, Stewart DJ. Angiogenic gene therapy in a porcine model of chronic myocardial ischemia: A comparison of angiopoietin-1 and VEGF. Circulation 2001;104(Suppl):II-262.

43. Kutryk MJB, Fitchett DF, Freeman M, Chisholm RJ, Cheema J, SloninkoJ, Dunne R, Camack N, Stewart DJ. The clinical safety and efficacy of direct intramyocardial plasmid DNA injections of VEGF165: Results of the SMART-2 Trial. *Can J Cardiol* 2002;18(Suppl B);189B.
44. Verma S, Kuliszewski MA, Mickle RD, Weisel RD, Fedak PWM, Li SH, Stewart DJ, Kutryk MJB. C-Reactive protein attenuates endothelial cell survival and differentiation. *Can J Cardiol* 2002;18(Suppl B);200B-201B.
45. Kuliszewski MA, Duttaroy S, Robb M, Ledet T, Steinbruchel D, Stewart DJ, Kutryk MJB. Integration and survival of angiopoietin-1 transfected vascular cells in the rat myocardium. *Can J Cardiol* 2002;18(Suppl B);226B-227B.
46. Kuliszewski MA, Verma S, Mickle DAG, Weisel RD, Fedak PWM, Li SH, Stewart DJ, Kutryk MJB. Rosiglitazone promotes endothelial progenitor cell differentiation in vitro. *Can J Cardiol* 2002;18(Suppl B);124B.
47. Kutryk MJB, Fitchett DF, Chisholm RJ, Freeman M, Cheema A, Stewart DJ. The direct percutaneous intramyocardial injection of plasmid DNA encoding VEGF165 is clinically safe. *Circulation* 2002;106(Suppl II);II-70.
48. Kutryk MJB, Kuliszewski MA. Progenitor cell capture for the accelerated endothelialization of endovascular devices. *Am. J Cardiol.* 2002;90(Suppl 6A):73H-74H.
49. Kutryk MJB, Kuliszewski MA. Endothelial progenitor cell capture for the accelerated endothelialization of stented arterial segments: autoseeding of endoluminal devices. *Arquivos Brasileiros de Cardiologia.* 2003;81(Suppl 1):5.
51. Lekas MC, Ball W, Kutryk MB, Proteau GA, Stewart DJ. Altered expression profile of angiopoietin-1 and -2 in a rat model of chronic limb ischemia. *Can J Cardiol*;2003;19(Suppl A):182A.
52. Kutryk MJB, Kuliszewski MA, Leclerc Y. Endothelial progenitor cells capture for the accelerated endothelialization of stented arterial segments and vascular grafts. *Can J Cardiol*;2003;19(Suppl A):237A
53. Verma S, Kuliszewski MA, Weisel R, Li S-H, Szmitko PE, Badiwala MV, Wang C-H, Kutryk MJ, Stewart D. C-Reactive protein attenuates endothelial progenitor cell survival and differentiation. *Circulation* 2003;108(Suppl IV):IV-302.

54. Kuliszewski MA, Zucco L, Faughnan M, Swan L, Therrien J, Stewart DJ, Kutryk MJ. Phenotypic characterization of circulating endothelial progenitor cells in genetically-determined vascular disorders. *Circulation* 2003;108(Suppl IV):IV-524.
55. Kutryk MJ, Kuliszewski MA. In vivo endothelial progenitor cell seeding of stented arterial segments and vascular grafts. *Circulation* 2003;108(Suppl IV):IV-573.
56. Zucco L, Kuliszewski MA, Horlick E, Swan L, Therrien J, Stewart DJ, Kutryk MJ. Abnormalities in function and phenotype of circulating endothelial progenitor cells have been found in patients with aortic coarctation. *Can J Cardiol* 2004;20(Suppl D):69-70D.
57. Kuliszewski MA, Zucco L, DiFabio MJ, Parker JD, Granton J, Stewart DJ, Kutryk MJ. Endothelial progenitor cell function, differentiation and survival is reduced in patients with idiopathic pulmonary arterial hypertension. *Can J Cardiol* 2004;20(Suppl D):67D.
58. Kuliszewski MA, Zucco L, Faughnan M, Hutchinson S, Stewart DJ, Kutryk MJ. Phenotypic and functional characterization of circulating endothelial progenitor cells in patients with hereditary hemorrhagic telangiectasia. *Can J Cardiol* 2004;20(Suppl D):67D.
59. Lekas MC, Ball W, Kutryk MB, Stewart DJ. Direct intramuscular injection of angiopoietin-2 augments neovascularization in a rat model of chronic limb ischemia. *Can J Cardiol* 2004;20(Suppl D):136D.
60. Kutryk MJ, Kulizewski MA. Reduction of neointimal hyperplasia by the rapid in-situ capture of circulating endothelial progenitor cells in a pig coronary stent model. *Can J Cardiol* 2004;20(Suppl D):166D.
61. Kuliszewski MA, Zucco L, DiFabio JM, Parker JD, Granton J, Stewart DJ, Kutryk MJ. Reduction in function and differentiation of endothelial progenitor cells in patients with primary pulmonary hypertension. *Circulation* 2004;17(Suppl III):III-19-20.
62. Kuliszewska KT, Kuliszewski MA, Karoubi G, Kang X, Courtman DW, Granton J, Kutryk MB, Stewart DJ. BMPR-2 signaling promotes pulmonary arterial endothelial cell survival: Implications for the pathogenesis of primary pulmonary hypertension. *Circulation* 2004;17(Suppl III):III-132.
63. Lekas MC, Ball W, Kutryk MJB, Zhang Q, Stewart DJ. Local gene transfer of angiopoietin-2 accelerates collateralization of the rat ischemic hindlimb. *J Am Coll Cardiol* 2005;45(Suppl A):377A.
64. Aoki J, Ong AT, McFadden EP, van der Giessen WJ, Sianos G, Regar E, de Feyter PJ, Kutryk MJ, Serruys PW. Endothelial progenitor cell capture by stents coated with

antibody against CD34. The HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45(Suppl A):69A.

65. Lekas MC, Ball W, Kutryk MJB, Stewart DJ. Therapeutic revascularization induced by angiopoietin-2 gene transfer is synergistically enhanced by combination with VEGF gene in the rat ischemic hindlimb model. Exp Clin Cardiol 2005;10:45.

Reviews and Editorials:

1. Camenzind E, Kutryk MJB, Serruys PW. Prevention of restenosis. Use of locally delivered conventional drug therapies. Semin Intervent Cardiol 1996;1:67-76.
2. Kutryk MJB, Serruys PW. Platelet activation and coronary interventions. Eur Heart J 1996;17:1134-1136.
3. Kutryk MJB, Serruys PW. Prevention of restenosis after PTCA. Vessels 1996;2(2):4-12.
4. Serruys PW, Kutryk MJB. The state of the stent: current practices, controversies and future trends. Am J Cardiol 1996;78(suppl 3A):4-7.
5. Herrman JPR, Kutryk MJB, Serruys PW. Clinical trials of direct thrombin inhibitors during invasive procedures. Thromb Haemost. 1997;78:367-376.
6. Kutryk MJB, van Dortmont LMC, de Crom RPG, van der Kamp AWM, Verdouw PD, van der Giessen WJ. Seeding of intravascular stents by the xenotransplantation of genetically modified endothelial cells. Semin Intervent Cardiol 1998;3:217-220.
7. Holmes DR, Kutryk M, Simari RD, Serruys PW. C-myc antisense for restenosis. Current Interventional Cardiology Reports 1999;1:63-65.
8. Kutryk MJB, Stewart DJ. Cardiac angiogenesis: An emerging technology for the treatment of CAD (Part I). Perspect Cardiol 2001;17:47-55.
9. Kutryk MJB, Stewart DJ. Cardiac angiogenesis: An emerging technology for the treatment of CAD (Part II). Perspect Cardiol 2001;17:47-58.
10. Kutryk MJB, Kassam SA, Stewart DJ. Angiogenesis: An emerging technology for the treatment of coronary artery disease. Cardiology Rounds 2001;6(6):1-8.
11. Kutryk MJB. Drug-eluting stents for the treatment of coronary artery disease. Part 1: Background and trials with paclitaxel. Cardiology Rounds 2002;7(6):1-6.

12. Kutryk MJB. Drug-eluting stents for the treatment of coronary artery disease. Part 2: Trial with rapamycin and other coating agents. *Cardiology Rounds* 2002;7(7):1-6.
13. Fitchett D, Kutryk M, Cheema A, Stewart D. Electro-mechanical mapping of the left ventricle for the assessment of myocardial viability. A platform for intramyocardial injection of gene therapy to promote myocardial angiogenesis. *Int. J. Bioelectromagnetism* 2002;4:75-76.
14. Kutryk MJB, Stewart DJ. Angiogenesis of the heart. *Micros. Res. Tech.* 2003;60:138-158.
15. Szmitko PE, Fedak PWM, Weisel RD, Stewart DJ, Kutryk MJB, Verma S. Endothelial progenitor cells. New hope for a broken heart. *Circulation* 2003;107:3093-3100.
16. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician Guide to Angiogenesis. *Circulation* 2003;108 2613-2618.
17. Kutryk MJB. Drug-eluting stents for the treatment of coronary artery disease. Part 3: New results from clinical trials. *Cardiology Rounds* 2003;8(9):1-6
18. Kutryk MJB. Drug-eluting stents for the treatment of coronary artery disease. Part 4: New results from clinical trials and future directions. *Cardiology Rounds* 2003;8(10):1-6
19. Lekas M, Kutryk MJ, Latter DA, Stewart DJ. Therapeutic neovascularization for ischemic heart disease. *Can J Cardiol.* 2004; (Suppl B):49B-57B.
20. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. Role of the endothelium in modulating neointimal formation. Vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. *J Am Coll Cardiol.* 2004;44:733-739.
21. Ong AT, Aoki J, Kutryk MJ, Serruys PW. How to accelerate the endothelialization of stents. *Arch Mal Coeur Vaiss.* 2005;98:123-126.

Book Chapters:

1. Kutryk MJB, Serruys PW. Stenting. In: Topol EJ (ed), *Textbook of Cardiovascular Medicine*. Philadelphia: Lippincott-Raven, 1997.
2. Kutryk MJB, Serruys PW. Introduction to coronary artery stenting: background, different

- types, newer designs, general principles. In: Pepine CJ (ed), *Diagnostic and Therapeutic Cardiac Catheterization*. Baltimore: Williams and Wilkins, 1998.
3. Kutryk MJB, Serruys PW. Stents: the menu. In Topol EJ (ed), *Textbook of Interventional Cardiology, 3rd edition*. Philadelphia: W.B. Saunders Company, 1998.
 4. Kutryk MJB, Serruys PW. Stenting. In: Topol EJ (ed), *Comprehensive Cardiovascular Medicine*. Philadelphia: Lippincott-Raven, 1998.
 5. Kutryk MJB, Serruys PW. Antirestenosis alternatives for the next millennium. In: Waksman R (ed), *Vascular Brachytherapy, 2nd Edition*. Armonk: Futura Publishing Company, Inc., 1998.
 6. Foley DP, Kutryk MJB. Self-expanding stents. In: Ellis S and Holmes D (eds), *Strategic Approaches in Coronary Intervention, 2nd edition*. Philadelphia: Lippincott Williams and Wilkins, 1999.
 7. Kutryk M, White H. Acute coronary syndromes. In: Curzen N and Rothman MT (eds), *Coronary Artery Stenting: A Case Oriented Approach*. London: Martin Dunitz Ltd., 2001.
 8. Kutryk MJB, Kassam SA, Stewart DJ. Therapeutic angiogenesis for coronary artery disease. In: Serruys PW, Leon MB, Colombo A, Kutryk MJB (eds), *Coronary Lesions: A Pragmatic Approach*. London: Martin Dunitz Ltd., 2001.
 9. Kutryk MJB, Serruys PW. Stents: the menu. In: Topol EJ (ed), *Textbook of Interventional Cardiology, 4th edition*. Philadelphia: W.B. Saunders Company, 2002.
 10. Kutryk MJB, Stewart DJS. Pharmacologic revascularization. In: Thérout P (ed), *Acute coronary syndromes. A companion to Braunwald's Heart Disease*. Philadelphia: Elsevier Science, 2003.
 11. Kutryk MJB. Coronary rupture and tamponade. In: Rothman M (ed), *Case studies in interventional cardiology*. Trowbridge: Cromwell Press, 2004.
 12. Kutryk MJB, Serruys PW. Local delivery of antisense oligomers to c-myc for the prevention of restenosis. In: Edoardo Camenzind and Ivan De Scheerder (eds), *Local Drug Delivery for Coronary Artery Disease Established and Emerging Applications*. London: Taylor & Francis Group, 2005.

1. Kutryk MJB, Serruys PW. *Current State of Coronary Stenting*. Rotterdam: Barejesteh van Wallijk van Doorn and Co's Uitgeversmaatschappij, 1997.
2. Serruys PW, Kutryk MJB (eds). *Handbook of Coronary Stents*, 2nd edition. London: Martin Dunitz Ltd., 1998.
3. Kutryk MJB, Serruys PW. *Coronary Stenting: Current Perspectives. A Companion to the Handbook of Coronary Stents*. London: Martin Dunitz Ltd., 1999.
4. Serruys PW, Kutryk MJB (eds). *Handbook of Coronary Stents*, 3rd edition. London: Martin Dunitz Ltd., 2000.
5. Serruys PW, Leon MB, Colombo A, Kutryk MJB (eds). *Coronary Lesions: A Pragmatic Approach*. London: Martin Dunitz Ltd., 2001.

I. INVITED LECTURES

1. Current state of drug delivery. Fifth Meeting of Advanced Interventional Cardiology, Cortina d'Ampezzo, Italy. February 12-15, 1997.
2. Oligonucleotides against c-myc. Third Drug Delivery Meeting, Amsterdam, The Netherlands. February 20-22, 1997.
3. Different types of stents: features and benefits. International Workshop "Coronary Stenting and Remodeling". Positano, Italy. May 2-3, 1997.
4. Local delivery of antisense oligonucleotide LR-3280 against c-myc for the prevention of in-stent restenosis: the Italics trial. IBC's Fourth Annual International Conference on Restenosis. Cambridge MA, USA. October 16-17, 1997.
5. ITALICS (Wallstent and antisense against c-myc); The big parade of stents. Fourth Thoraxcenter Course on Coronary Stenting. Rotterdam, The Netherlands. December 9-13 1997.
6. Trial of beta radiation for restenosis; Eurovegas study (Angiojet); Comparison of stents; BENESTENT: final analysis with cost effectiveness studies; Randomized study of laser wire vs. conventional wires for chronic total occlusions; ITALICS trial - local delivery of placebo vs. antisense to SMC DNA after Wallstent implantation. Thirteenth Annual International Symposium: Interventional Cardiology. Snowmass Village, Colorado. March 1-6, 1998.

7. The concept of the helical DNA ladder design of the R stent. Endovascular Therapy Course (ETC). Paris, France. May 5-8, 1998.
8. The ITALICS study. Hotline Session, European Congress of Cardiology. Vienna, Austria. August 22-26, 1998.
9. The Thoraxcenter "Big Stent Parade": emphasizing "new" stent designs; A cavalcade of the newest stent designs: The Jomed stent family. Faculty, Transcatheter Therapeutics (TCT). Washington DC. October 7-11, 1998.
10. Novelties in stent design. Fifth Heart Center Course on Coronary Stenting. Rotterdam, The Netherlands. December 8-12, 1998.
11. Transmyocardial percutaneous revascularization and angiogenesis in patients unamenable to conventional revascularization, the pharmacological and genetic approach; Stents for bifurcation and bifurcated stents. Sixth Meeting of Advanced Interventional Cardiology, Cortina d'Ampezzo, Italy. February 17-20, 1999.
12. Dedicated bifurcation stents: a technical overview; Non-FDA approved stents – a view to the future. Faculty, Transcatheter Therapeutics (TCT), Washington DC. September 22-26, 1999.
13. Lesion-specific stenting: the right stent, the right approach. Faculty, Transcatheter Therapeutics (TCT), Washington DC. October 19-22, 2000.
14. Myocardial angiogenesis: overview of the clinical trials. Canadian Cardiovascular Congress, Vancouver, BC. October 29-November 1, 2000.
15. In vivo progenitor cell capture for the accelerated endothelialization of endovascular devices. The Paris Course on Revascularization (PCR), Paris, France. May 21-24, 2002.
16. Myocardial angiogenesis. University of Florida Health Science Center/Jacksonville, May 29, 2002.
17. Recruitment of progenitor endothelial cells. Faculty, Transcatheter Therapeutics (TCT), Washington DC. September 24-28, 2002.
18. The future beyond drug-eluting stents; Proffered paper: Immobilized anti-EPC antibodies and the reconstitution of endothelial cells. Faculty, International Symposium on Endovascular Therapy (ISET), Miami FL. January 19-23, 2003.

19. Immobilized anti-EPC antibodies for the promotion of endothelialization. Faculty, Local Drug Delivery Meeting and Cardiovascular Course on Radiation and Molecular Strategies (LDDR), Geneva Switzerland. January 23-25, 2003.
20. The relative effects of angiopoietin-1 vs. VEGF on collateral flow in a porcine model of chronic ischemia. Faculty, Cardiovascular Radiation Therapy (CRT), Washington DC. January 26-29, 2003.
21. Beyond drug eluting stents: accelerated endothelial coverage; Capturing progenitor endothelial cells: the ultimate stent coating and a novel approach to prevent restenosis. Faculty, The Paris Course on Revascularization (EuroPCR), Paris, France. May 20-23, 2003.
22. How important is stent design in the era of drug eluting stents? Open cells vs closed cells; New possibilities for preventing restenosis I: progenitor cells. Faculty, IX Congress of SOLACI, São Paulo, Brazil. July 23-25, 2003.
23. Endothelial progenitor cell recruitment to accelerate healing and reduce restenosis; Endothelial regeneration is the key! A different approach to restenosis – the pro-healing concept; The Orbus Genous Stent Program: Can rapid endothelialization of a stent with progenitor endothelial cells reduce restenosis? Faculty, Transcatheter Therapeutics (TCT), Washington, DC. September 15-19, 2003.
24. EPC capture coating: How far is the future? Faculty, GCI-Global Cardiovascular Interventions, Frankfurt/Main, Germany, November 28-29, 2003.
25. The future beyond drug-eluting stents: Progenitor endothelial cell capture. Faculty, International Symposium on Endovascular Therapy (ISET), Miami FL. January 25-29, 2004.
26. Vascular tolerance to: biological polymer with molecular binding technology. Faculty, Local Drug Delivery Meeting and Cardiovascular Course on Radiation and Molecular Strategies (LDDR), Geneva Switzerland. January 29-31, 2004.
27. The Genous endothelial cell capture approach: Concept, experimental results, and the HEALING I and II clinical trials. Enter The Drug-Eluting Stent Revolution III: Clinical Impact and Evolving Perspectives. American College of Cardiology, New Orleans, LA. March 6, 2004.
28. Endothelial progenitor cell capture on stent platforms: A novel approach to thrombo-resistance and restenosis prevention. Faculty, Nineteenth Annual International Symposium: Interventional Cardiology. Snowmass Village, Colorado. March 22-26, 2004.

29. Judging a stent by its cover: What does the era of coated stents mean for your patient? Faculty, St. Michael's Hospital Cardiology Day. Toronto, Ontario. April 03, 2004
30. A pro-healing approach to stent thrombo-resistance and restenosis prevention: Endothelial progenitor cell capture. Faculty, Angioplasty Summit 2004. Seoul, Korea. April 29-May 1, 2004.
31. Progenitor endothelial cells on a stent: The Orbus Program. Faculty, Cardiovascular Radiation Therapy (CRT), Washington DC. May 5-7, 2004.
32. Accelerated endothelialization by endothelial progenitor cell capture to promote vascular healing: The HEALING clinical trials. Faculty, The Paris Course on Revascularization (EuroPCR), Paris, France. May 25-28, 2004.
33. Stem Cells, EPC and New Pro-Healing Strategies in PCI. Faculty. 13th Interventional Cardiology Live Course, Montreal, Quebec. June 9-11, 2004.
34. A pro-healing approach to thrombo-resistance and restenosis prevention: Endothelial progenitor cell capture; Endothelial progenitor capture for the passivation of endoluminal devices – promotion of vascular healing. Faculty, Tokyo Percutaneous Coronary Intervention Conference (TOPIC), Tokyo, Japan. July 22-24, 2004.
35. Capturing circulation endothelial progenitor cells: A novel approach to prevent thrombosis and minimize restenosis; Beyond DES. Endothelial progenitor cell capture. The GENOUS stent. Faculty, Singapore International Cardiovascular Therapeutics (SICT). Singapore, Republic of Singapore. August 5-7, 2004.
36. How to heal blood vessels. Faculty. International New Cardiovascular Technology Congress (INCTC). Quebec City, Quebec. September 10,11, 2004.
37. Endothelial progenitor capture for the passivation of endoluminal devices - promotion of vascular healing. University Rounds. Toronto, Ontario. October 7, 2004.
38. The future beyond drug-eluting stents: Progenitor endothelial cell capture. Faculty. Singapore Live 2005 – 14th Annual Live Interventions in Vascular Endotherapy. Singapore, Republic of Singapore. January 24-26, 2005.
39. Endothelial progenitor cell capture for the prevention of stent thrombosis and restenosis. Faculty. 11th Local Drug Delivery Meeting and Cardiovascular Course on Radiation and Molecular Strategies (LDDR), Geneva Switzerland. February 3-5, 2005.

40. Genous endothelial progenitor cell capture. Faculty. Enter The Drug-Eluting Stent Revolution IV: A Critical Appraisal. American College of Cardiology, Orlando, FL. March 5, 2005.
41. Endothelial progenitor cell coating. Faculty. Interventional Cardiology 2005: Twentieth Annual International Symposium: Interventional Cardiology. Snowmass Village, Colorado. March 22-26, 2005.
42. Progenitor Cells Healing I and II. Drug Eluting Stents In-Depth. Faculty. Cardiovascular Revascularization Therapies (CRT), Washington, DC. March 28-31, 2005.
43. Stem Cell Therapy: The PHACET Trial. Faculty. Cardiology for the Practitioner: Critical Pathways. Toronto, Ontario. April 16, 2005.
44. Molecular approaches to prevent restenosis using novel stent strategies. National Research Forum for Young Investigators in Circulatory and Respiratory Health. Winnipeg, Manitoba. April 26-May 1, 2005.

J. PATENTS

1. Kutryk MJB, Cottone RJ, Rowland SM. Coating that promotes endothelial cell adherence. IPN: WO 01/68158

revised October 2004